Support and Resistance Levels
Past performance
About Alivus Life Sciences Ltd Glenmark Life Sciences Limited, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs). Originally incorporated as Zorg Laboratories Private Limited in 2011, the company underwent significant transformations, including its acquisition by Glenmark Pharmaceuticals in 2018 and its conversion to a public limited company. The company's API division, acquired from its parent company in 2019, underscores its strategic focus in the pharmaceutical sector.
Glenmark Life Sciences has strategically expanded its manufacturing capabilities, with facilities in Ankleshwar, Dahej, Kurkumbh, and Mohol. Notable expansions in 2023 include a 240 KL increase at Dahej and a 192 KL expansion at Ankleshwar. The company raised Rs 1513.6 crores through an IPO in August 2021, highlighting its growth ambitions. With a robust portfolio and continuous capacity enhancements, Glenmark Life Sciences is well-positioned in the global API market.